Seres Therapeutics, Inc. (MCRB) stock
MCRBNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.24−0.09 (-6.77%)
Close on Nov 20, 2026Market cap $12.33MP/E –Yield –
Seres Therapeutics free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Seres Therapeutics's free cash flow for the twelve months ending Jun 30, 2026 was -$51.30M. For fiscal 2025 it was $865.00K. The highest annual figure on record is $22.43M in fiscal 2016.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $865.00K | – |
| FY2024 | Dec 31, 2024 | -$148.99M | – |
| FY2023 | Dec 31, 2023 | -$125.33M | – |
| FY2022 | Dec 31, 2022 | -$238.64M | – |
| FY2021 | Dec 31, 2021 | -$2.88M | – |
| FY2020 | Dec 31, 2020 | -$94.20M | – |
| FY2019 | Dec 31, 2019 | -$77.52M | – |
| FY2018 | Dec 31, 2018 | -$64.79M | – |
| FY2017 | Dec 31, 2017 | -$80.20M | -457.6% |
| FY2016 | Dec 31, 2016 | $22.43M | – |
| FY2015 | Dec 31, 2015 | -$45.21M | – |
| FY2014 | Dec 31, 2014 | -$11.36M | – |
| FY2013 | Dec 31, 2013 | -$5.50M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$22.39M | – |
| Q1 FY2026 | Mar 31, 2026 | -$16.36M | -160.9% |
| Q4 FY2025 | Dec 31, 2025 | -$14.74M | – |
| Q3 FY2025 | Sep 30, 2025 | $2.20M | – |
| Q2 FY2025 | Jun 30, 2025 | -$13.47M | – |
| Q1 FY2025 | Mar 31, 2025 | $26.88M | – |
| Q4 FY2024 | Dec 31, 2024 | -$38.97M | – |
| Q3 FY2024 | Sep 30, 2024 | -$34.81M | – |
| Q2 FY2024 | Jun 30, 2024 | -$39.91M | -161.6% |
| Q1 FY2024 | Mar 31, 2024 | -$35.30M | – |
| Q4 FY2023 | Dec 31, 2023 | -$48.38M | – |
| Q3 FY2023 | Sep 30, 2023 | -$61.05M | – |
| Q2 FY2023 | Jun 30, 2023 | $64.75M | – |
| Q1 FY2023 | Mar 31, 2023 | -$80.65M | – |
| Q4 FY2022 | Dec 31, 2022 | -$56.35M | – |
| Q3 FY2022 | Sep 30, 2022 | -$60.83M | -149.2% |
| Q2 FY2022 | Jun 30, 2022 | -$52.06M | – |
| Q1 FY2022 | Mar 31, 2022 | -$69.40M | – |
| Q4 FY2021 | Dec 31, 2021 | -$53.44M | – |
| Q3 FY2021 | Sep 30, 2021 | $123.65M | – |
| Q2 FY2021 | Jun 30, 2021 | -$42.25M | – |
| Q1 FY2021 | Mar 31, 2021 | -$30.84M | – |
| Q4 FY2020 | Dec 31, 2020 | -$18.15M | – |
| Q3 FY2020 | Sep 30, 2020 | -$25.93M | – |
| Q2 FY2020 | Jun 30, 2020 | -$25.79M | – |
| Q1 FY2020 | Mar 31, 2020 | -$24.32M | – |
| Q4 FY2019 | Dec 31, 2019 | -$14.28M | -211.0% |
| Q3 FY2019 | Sep 30, 2019 | -$18.42M | – |
| Q2 FY2019 | Jun 30, 2019 | -$12.13M | – |
| Q1 FY2019 | Mar 31, 2019 | -$32.70M | – |
| Q4 FY2018 | Dec 31, 2018 | $12.86M | – |
| Q3 FY2018 | Sep 30, 2018 | -$23.56M | – |
| Q2 FY2018 | Jun 30, 2018 | -$26.38M | – |
| Q1 FY2018 | Mar 31, 2018 | -$27.72M | – |
| Q4 FY2017 | Dec 31, 2017 | -$21.29M | – |
| Q3 FY2017 | Sep 30, 2017 | -$4.07M | – |
| Q2 FY2017 | Jun 30, 2017 | -$26.94M | – |
| Q1 FY2017 | Mar 31, 2017 | -$27.90M | – |
| Q4 FY2016 | Dec 31, 2016 | -$26.49M | – |
| Q3 FY2016 | Sep 30, 2016 | -$17.23M | – |
See a number that looks wrong?